Tissue Force Programs Cell Fate and Tumor Aggression. Read more about Tissue Force Programs Cell Fate and Tumor Aggression.
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Read more about Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer. Read more about BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer.
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Read more about Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Read more about Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Read more about BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Read more about Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Read more about CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. Read more about Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.
